EVLO News and Press, Evelo Biosciences Inc. From 07/18/22

Evelo Biosciences ( NASDAQ: EVLO ) appoints 25 years of finance and operations experienced Marella Thorell as CFO, effective September 1, 2022. Most recently she served as Chief Accounting Officer and previously as Head of Finance of Centessa Pharmaceuticals. ...

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, today announced the appointment of Marella Thorell as Chie...

Gainers: Cogent Biosciences (COGT) +89%. Redbox Entertainment (RDBX) +48%. Alpha Tau Medical (DRTS) +23%. Bright Green Corporation (BGXX) +17%. Aridis Pharmaceuticals (ARDS) +18%. Wah Fu Education Group (WAFU) +14%. Powerbridge Technologies (PBTS) +12%. Hycroft Mining Holding Corporation (HYM...

Today, we put Evelo Biosciences in the spotlight for the first time. The company has several potential catalysts on the horizon. The company also recently executed a large direct offering and brought aboard some strategic advisors as well. A full investment analysis follows in the...

Gainers: Tonix Pharmaceuticals Holding (TNXP) +60%. Helius Medical Technologies (HSDT) +40%. View (VIEW) +42%. Spark Networks (LOV) +32%. Regencell Bioscience Holdings (RGC) +21%. 180 Life Sciences (ATNF) +20%. Evelo Biosciences (EVLO) +17%. NeuroOne Medical Technologies Corporation (NMTC) +1...

=Gainers: BlackSky Technology (BKSY) +93%. StoneMor (STON) +51%. Genocea Biosciences (GNCA) +35%. Hoegh LNG Partners (HMLP) +31%. Caleres (CAL) +27%. Evelo Biosciences (EVLO) +20%. Spire Global (SPIR) +17%. Groupon (GRPN) +17%. Abercrombie & Fitch (ANF) +17%. Losers: Verrica Pharmaceutica...

Gainers: Elevation Oncology (ELEV) +20%. Cue Biopharma (CUE) +14%. Evelo Biosciences (EVLO) +13%. GeoVax Labs (GOVX) +13%. Immix Biopharma (IMMX) +9%. Losers: Verrica Pharmaceuticals (VRCA) -58%. PMV Pharmaceuticals (PMVP) -10%. TransMedics (TMDX) ...

Biotechnology company Evelo Biosciences (NASDAQ:EVLO) entered into a securities purchase agreement with investors over direct offering of 54,246,358 shares at $1.46 per share. The offering will result in gross proceeds of $79.2M. The offering is being led by Evelo Founder Flagship Pionee...

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agreement with investors in a registered ...

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence of the First Quarter 2022 Financial Results (Unaudited) section, the dates should be &...